December 16, 2025

A Historic Step Forward: Duchenne Added to Newborn Screening

We congratulate Parent Project Muscular Dystrophy (PPMD), the Muscular Dystrophy Association (MDA), the U.S. Department of Health and Human Services (HHS), and the Health Resources and Services Administration (HRSA), as well as all partner organizations, allies and families living with Duchenne on this historic achievement: the addition of Duchenne muscular dystrophy to the Recommended Uniform Screening Panel (RUSP). This milestone reflects years of tireless advocacy and collaboration led by resilient families and dedicated organizations committed to earlier diagnosis and better outcomes.

We are honored to stand alongside these courageous families as we work to deliver meaningful functional improvement for people living with neuromuscular diseases. With Duchenne now included in newborn screening, more families will have the opportunity to receive an earlier diagnosis, potentially accelerating and expanding access to clinical care and therapies.

Thank you to PPMD, MDA, HHS, HRSA, policymakers and the entire Duchenne community for your partnership, perseverance and unwavering hope.

With gratitude and hope,

The Dyne Therapeutics Team